schliessen

Filtern

 

Bibliotheken

Cover Image

Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients

We evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy. This was a follow-up observational study involving all 79 patients (35%; 62 men, 17 women) with NRA from a cohort of... Full description

Journal Title: Diabetologia 2005, Vol.48 (11), p.2241-2247
Main Author: ROSSING, K
Other Authors: CHRISTENSEN, P. K , HOVIND, P , PARVING, H.-H
Format: Electronic Article Electronic Article
Language: English
Subjects:
Aged
Albuminuria - complications
Albuminuria - epidemiology
Angiotensin
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological and medical sciences
Care and treatment
Chronic kidney failure
Cohort Studies
Development and progression
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Diabetes. Impaired glucose tolerance
Diabetic nephropathies
Diabetic Neuropathies - complications
Diabetic Neuropathies - drug therapy
Diabetic Neuropathies - epidemiology
Diabetics
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Follow-Up Studies
Humans
Incidence
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - etiology
Kidney Failure, Chronic - mortality
Kidneys
Male
Medical sciences
Middle Aged
Mortality
Nephrology. Urinary tract diseases
Patient outcomes
Risk Factors
Survival Rate
Type 2 diabetes
Urinary system involvement in other diseases. Miscellaneous
Publisher: Berlin: Springer
ID: ISSN: 0012-186X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_68796704
title: Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
format: Article
creator:
  • ROSSING, K
  • CHRISTENSEN, P. K
  • HOVIND, P
  • PARVING, H.-H
subjects:
  • Aged
  • Albuminuria - complications
  • Albuminuria - epidemiology
  • Angiotensin
  • Angiotensin II Type 1 Receptor Blockers - therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors - therapeutic use
  • Biological and medical sciences
  • Care and treatment
  • Chronic kidney failure
  • Cohort Studies
  • Development and progression
  • Diabetes Mellitus, Type 2 - complications
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes Mellitus, Type 2 - mortality
  • Diabetes. Impaired glucose tolerance
  • Diabetic nephropathies
  • Diabetic Neuropathies - complications
  • Diabetic Neuropathies - drug therapy
  • Diabetic Neuropathies - epidemiology
  • Diabetics
  • Endocrine pancreas. Apud cells (diseases)
  • Endocrinopathies
  • Etiopathogenesis. Screening. Investigations. Target tissue resistance
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Kidney Failure, Chronic - epidemiology
  • Kidney Failure, Chronic - etiology
  • Kidney Failure, Chronic - mortality
  • Kidneys
  • Male
  • Medical sciences
  • Middle Aged
  • Mortality
  • Nephrology. Urinary tract diseases
  • Patient outcomes
  • Risk Factors
  • Survival Rate
  • Type 2 diabetes
  • Urinary system involvement in other diseases. Miscellaneous
ispartof: Diabetologia, 2005, Vol.48 (11), p.2241-2247
description: We evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy. This was a follow-up observational study involving all 79 patients (35%; 62 men, 17 women) with NRA from a cohort of type 2 diabetic patients with nephropathy that was followed for at least 3 years at the Steno Diabetes Center (n=227). Patients were followed from the onset of NRA until death or January 2005. The mean age (+/-SD) was 60+/-8 years and known diabetes duration was 14+/-7 years. Remission of NRA was defined as sustained albuminuria
language: eng
source:
identifier: ISSN: 0012-186X
fulltext: no_fulltext
issn:
  • 0012-186X
  • 1432-0428
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2682176
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_68796704
sourceformatXML
sourcesystemPC
galeidA328383030
sourcerecordidA328383030
originalsourceidFETCH-LOGICAL-1470t-57582c73cc081589f90a68a4485bf8bd68748d47fde4127265e3b454350372890
addsrcrecordideNp9kV-L1TAQxYso7t3VD-CLFEXfuk7-NenjsugqLAii4FtI0-matU1r0l7YVz-5U-6FxUUkD4HM78yczCmKFwzOGYB-lwEYVxWAqlgjdFU_KnZMCl6B5OZxsdvKFTP195PiNOdbABBK1k-LE1YzDYqJXfH7C44h5zDFcurLiPOPNC3BV8nFGyzd0K5jiGsKrkzYrR5zmUL-ubEYuyovjqiE0Q1lFzK6TJrYlWGc07QnOK9pH_ZUDbFc7mYsOXGuRRpRzm4JGJf8rHjSuyHj8-N9Vnz78P7r5cfq-vPVp8uL64pJDUultDLca-E9GKZM0zfgauOkNKrtTdvVRkvTSd13KBnXvFYoWqmkUCA0Nw2cFW8PfcnbrxXzYunnHofBRZzWbKlBU2uQBL56AN5Oa6I_ZsuZMLI2DSPo9QG6cQPaEPtpSc5vHe2F4EYYAQKIOv8HRaejtfspYh_o_S8BOwh8mnJO2Ns5hdGlO8vAbqHbQ-iWQrdb6LYmzcuj37UdsbtXHFMm4M0RcNm7oadwfcj3HK0HOGwb0g-G-7BQSlMk12H4j4U_OqXEJg
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid213846891
display
typearticle
titleRemission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
creatorROSSING, K ; CHRISTENSEN, P. K ; HOVIND, P ; PARVING, H.-H
creatorcontribROSSING, K ; CHRISTENSEN, P. K ; HOVIND, P ; PARVING, H.-H
descriptionWe evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy. This was a follow-up observational study involving all 79 patients (35%; 62 men, 17 women) with NRA from a cohort of type 2 diabetic patients with nephropathy that was followed for at least 3 years at the Steno Diabetes Center (n=227). Patients were followed from the onset of NRA until death or January 2005. The mean age (+/-SD) was 60+/-8 years and known diabetes duration was 14+/-7 years. Remission of NRA was defined as sustained albuminuria <600 mg/24 h for at least 1 year. The duration of follow-up after onset of NRA was 6.5 years (range 2-20 years). Remission was induced in 20 (25%) of the patients, all treated with ACE inhibitors or angiotensin-II receptor blockers. Remission lasted 4.1 years (range 1-10 years) and only three patients relapsed. At the end of follow-up, only 30% (two ESRD and four deaths) of the 20 patients with remission had reached the composite endpoint of ESRD or death, in contrast to 66% (16 ESRD and 23 deaths) of the 59 patients without remission (p<0.01). Cox regression analysis revealed that remission was associated with a risk reduction of 67% (95% CI 10-87) for reaching the composite endpoint of ESRD or death and of 69% (95% CI 21-88%) for death alone. Male sex, greater age and systolic blood pressure at onset of NRA were also independently associated with an increased risk of ESRD and death. Aggressive antihypertensive treatment can lead to long-term remission of NRA in a sizeable proportion of patients with type 2 diabetes. Such remission is associated with a slower progression of nephropathy and substantially improved survival.
identifier
0ISSN: 0012-186X
1EISSN: 1432-0428
2DOI: 10.1007/s00125-005-1937-6
3PMID: 16170513
languageeng
publisherBerlin: Springer
subjectAged ; Albuminuria - complications ; Albuminuria - epidemiology ; Angiotensin ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Care and treatment ; Chronic kidney failure ; Cohort Studies ; Development and progression ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - mortality ; Diabetes. Impaired glucose tolerance ; Diabetic nephropathies ; Diabetic Neuropathies - complications ; Diabetic Neuropathies - drug therapy ; Diabetic Neuropathies - epidemiology ; Diabetics ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Follow-Up Studies ; Humans ; Incidence ; Kidney Failure, Chronic - epidemiology ; Kidney Failure, Chronic - etiology ; Kidney Failure, Chronic - mortality ; Kidneys ; Male ; Medical sciences ; Middle Aged ; Mortality ; Nephrology. Urinary tract diseases ; Patient outcomes ; Risk Factors ; Survival Rate ; Type 2 diabetes ; Urinary system involvement in other diseases. Miscellaneous
ispartofDiabetologia, 2005, Vol.48 (11), p.2241-2247
rights
02006 INIST-CNRS
1COPYRIGHT 2005 Springer
2Springer-Verlag 2005
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1470t-57582c73cc081589f90a68a4485bf8bd68748d47fde4127265e3b454350372890
citesFETCH-LOGICAL-1470t-57582c73cc081589f90a68a4485bf8bd68748d47fde4127265e3b454350372890
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17280209$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16170513$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0ROSSING, K
1CHRISTENSEN, P. K
2HOVIND, P
3PARVING, H.-H
title
0Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
1Diabetologia
addtitleDiabetologia
descriptionWe evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy. This was a follow-up observational study involving all 79 patients (35%; 62 men, 17 women) with NRA from a cohort of type 2 diabetic patients with nephropathy that was followed for at least 3 years at the Steno Diabetes Center (n=227). Patients were followed from the onset of NRA until death or January 2005. The mean age (+/-SD) was 60+/-8 years and known diabetes duration was 14+/-7 years. Remission of NRA was defined as sustained albuminuria <600 mg/24 h for at least 1 year. The duration of follow-up after onset of NRA was 6.5 years (range 2-20 years). Remission was induced in 20 (25%) of the patients, all treated with ACE inhibitors or angiotensin-II receptor blockers. Remission lasted 4.1 years (range 1-10 years) and only three patients relapsed. At the end of follow-up, only 30% (two ESRD and four deaths) of the 20 patients with remission had reached the composite endpoint of ESRD or death, in contrast to 66% (16 ESRD and 23 deaths) of the 59 patients without remission (p<0.01). Cox regression analysis revealed that remission was associated with a risk reduction of 67% (95% CI 10-87) for reaching the composite endpoint of ESRD or death and of 69% (95% CI 21-88%) for death alone. Male sex, greater age and systolic blood pressure at onset of NRA were also independently associated with an increased risk of ESRD and death. Aggressive antihypertensive treatment can lead to long-term remission of NRA in a sizeable proportion of patients with type 2 diabetes. Such remission is associated with a slower progression of nephropathy and substantially improved survival.
subject
0Aged
1Albuminuria - complications
2Albuminuria - epidemiology
3Angiotensin
4Angiotensin II Type 1 Receptor Blockers - therapeutic use
5Angiotensin-Converting Enzyme Inhibitors - therapeutic use
6Biological and medical sciences
7Care and treatment
8Chronic kidney failure
9Cohort Studies
10Development and progression
11Diabetes Mellitus, Type 2 - complications
12Diabetes Mellitus, Type 2 - drug therapy
13Diabetes Mellitus, Type 2 - mortality
14Diabetes. Impaired glucose tolerance
15Diabetic nephropathies
16Diabetic Neuropathies - complications
17Diabetic Neuropathies - drug therapy
18Diabetic Neuropathies - epidemiology
19Diabetics
20Endocrine pancreas. Apud cells (diseases)
21Endocrinopathies
22Etiopathogenesis. Screening. Investigations. Target tissue resistance
23Female
24Follow-Up Studies
25Humans
26Incidence
27Kidney Failure, Chronic - epidemiology
28Kidney Failure, Chronic - etiology
29Kidney Failure, Chronic - mortality
30Kidneys
31Male
32Medical sciences
33Middle Aged
34Mortality
35Nephrology. Urinary tract diseases
36Patient outcomes
37Risk Factors
38Survival Rate
39Type 2 diabetes
40Urinary system involvement in other diseases. Miscellaneous
issn
00012-186X
11432-0428
fulltextfalse
rsrctypearticle
creationdate2005
recordtypearticle
recordideNp9kV-L1TAQxYso7t3VD-CLFEXfuk7-NenjsugqLAii4FtI0-matU1r0l7YVz-5U-6FxUUkD4HM78yczCmKFwzOGYB-lwEYVxWAqlgjdFU_KnZMCl6B5OZxsdvKFTP195PiNOdbABBK1k-LE1YzDYqJXfH7C44h5zDFcurLiPOPNC3BV8nFGyzd0K5jiGsKrkzYrR5zmUL-ubEYuyovjqiE0Q1lFzK6TJrYlWGc07QnOK9pH_ZUDbFc7mYsOXGuRRpRzm4JGJf8rHjSuyHj8-N9Vnz78P7r5cfq-vPVp8uL64pJDUultDLca-E9GKZM0zfgauOkNKrtTdvVRkvTSd13KBnXvFYoWqmkUCA0Nw2cFW8PfcnbrxXzYunnHofBRZzWbKlBU2uQBL56AN5Oa6I_ZsuZMLI2DSPo9QG6cQPaEPtpSc5vHe2F4EYYAQKIOv8HRaejtfspYh_o_S8BOwh8mnJO2Ns5hdGlO8vAbqHbQ-iWQrdb6LYmzcuj37UdsbtXHFMm4M0RcNm7oadwfcj3HK0HOGwb0g-G-7BQSlMk12H4j4U_OqXEJg
startdate2005
enddate2005
creator
0ROSSING, K
1CHRISTENSEN, P. K
2HOVIND, P
3PARVING, H.-H
general
0Springer
1Springer Nature B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117T5
127X7
137XB
1488E
158AO
168C1
178FI
188FJ
198FK
20ABUWG
21BENPR
22FYUFA
23GHDGH
24H94
25K9.
26M0S
27M1P
28PQEST
29PQQKQ
30PQUKI
31PRINS
327X8
sort
creationdate2005
titleRemission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
authorROSSING, K ; CHRISTENSEN, P. K ; HOVIND, P ; PARVING, H.-H
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1470t-57582c73cc081589f90a68a4485bf8bd68748d47fde4127265e3b454350372890
rsrctypearticles
prefilterarticles
languageeng
creationdate2005
topic
0Aged
1Albuminuria - complications
2Albuminuria - epidemiology
3Angiotensin
4Angiotensin II Type 1 Receptor Blockers - therapeutic use
5Angiotensin-Converting Enzyme Inhibitors - therapeutic use
6Biological and medical sciences
7Care and treatment
8Chronic kidney failure
9Cohort Studies
10Development and progression
11Diabetes Mellitus, Type 2 - complications
12Diabetes Mellitus, Type 2 - drug therapy
13Diabetes Mellitus, Type 2 - mortality
14Diabetes. Impaired glucose tolerance
15Diabetic nephropathies
16Diabetic Neuropathies - complications
17Diabetic Neuropathies - drug therapy
18Diabetic Neuropathies - epidemiology
19Diabetics
20Endocrine pancreas. Apud cells (diseases)
21Endocrinopathies
22Etiopathogenesis. Screening. Investigations. Target tissue resistance
23Female
24Follow-Up Studies
25Humans
26Incidence
27Kidney Failure, Chronic - epidemiology
28Kidney Failure, Chronic - etiology
29Kidney Failure, Chronic - mortality
30Kidneys
31Male
32Medical sciences
33Middle Aged
34Mortality
35Nephrology. Urinary tract diseases
36Patient outcomes
37Risk Factors
38Survival Rate
39Type 2 diabetes
40Urinary system involvement in other diseases. Miscellaneous
toplevelpeer_reviewed
creatorcontrib
0ROSSING, K
1CHRISTENSEN, P. K
2HOVIND, P
3PARVING, H.-H
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Immunology Abstracts
11Health & Medical Collection
12ProQuest Central (purchase pre-March 2016)
13Medical Database (Alumni Edition)
14ProQuest Pharma Collection
15Public Health Database
16Hospital Premium Collection
17Hospital Premium Collection (Alumni Edition)
18ProQuest Central (Alumni) (purchase pre-March 2016)
19ProQuest Central (Alumni Edition)
20ProQuest Central
21Health Research Premium Collection
22Health Research Premium Collection (Alumni)
23AIDS and Cancer Research Abstracts
24ProQuest Health & Medical Complete (Alumni)
25Health & Medical Collection (Alumni Edition)
26Medical Database
27ProQuest One Academic Eastern Edition
28ProQuest One Academic
29ProQuest One Academic UKI Edition
30ProQuest Central China
31MEDLINE - Academic
jtitleDiabetologia
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0ROSSING, K
1CHRISTENSEN, P. K
2HOVIND, P
3PARVING, H.-H
formatjournal
genrearticle
ristypeJOUR
atitleRemission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
jtitleDiabetologia
addtitleDiabetologia
date2005
risdate2005
volume48
issue11
spage2241
epage2247
pages2241-2247
issn0012-186X
eissn1432-0428
abstractWe evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy. This was a follow-up observational study involving all 79 patients (35%; 62 men, 17 women) with NRA from a cohort of type 2 diabetic patients with nephropathy that was followed for at least 3 years at the Steno Diabetes Center (n=227). Patients were followed from the onset of NRA until death or January 2005. The mean age (+/-SD) was 60+/-8 years and known diabetes duration was 14+/-7 years. Remission of NRA was defined as sustained albuminuria <600 mg/24 h for at least 1 year. The duration of follow-up after onset of NRA was 6.5 years (range 2-20 years). Remission was induced in 20 (25%) of the patients, all treated with ACE inhibitors or angiotensin-II receptor blockers. Remission lasted 4.1 years (range 1-10 years) and only three patients relapsed. At the end of follow-up, only 30% (two ESRD and four deaths) of the 20 patients with remission had reached the composite endpoint of ESRD or death, in contrast to 66% (16 ESRD and 23 deaths) of the 59 patients without remission (p<0.01). Cox regression analysis revealed that remission was associated with a risk reduction of 67% (95% CI 10-87) for reaching the composite endpoint of ESRD or death and of 69% (95% CI 21-88%) for death alone. Male sex, greater age and systolic blood pressure at onset of NRA were also independently associated with an increased risk of ESRD and death. Aggressive antihypertensive treatment can lead to long-term remission of NRA in a sizeable proportion of patients with type 2 diabetes. Such remission is associated with a slower progression of nephropathy and substantially improved survival.
copBerlin
pubSpringer
pmid16170513
doi10.1007/s00125-005-1937-6
oafree_for_read